It's funny how "scam" is always the term that bash
Post# of 1460
Posted On: 08/02/2016 10:43:07 AM
It's funny how "scam" is always the term that bashers fling when in fact it's the bashers who are trying to scam the company and unwary investors -- cheating the company by driving the stock price down so that the basher/short sellers can profit, and then cheating unwary shareholders either by inducing them to sell (possibly at a loss) because of basher scare tactics, or cheating them by driving the share price below where it should be, so that shareholders who DON'T sell are sitting there with their investment at a depressed level.
There are certainly questions about the competence of AVXL's management in the past. The new president seems to be righting the ship. People seem to be claiming to be disappointed by the data on the drug, but given that no other drug has displayed any sort of long-term efficacy against Alzheimer's, the fact that AVXL's drug seems to have SOME efficacy for about 6 months or so is something very positive. These are early days in the clinical trials. It could be that the dosing schedule or the dosage is not correct. Sometimes these drugs are more effective when taken spaced out further -- who knows? We sure don't. But ANY kind of positive result with Alzheimer's is a plus, not a minus.
I consider this to be a far more risky investment than CTIX and I have only a relatively small investment now in AVXL. I hope that they are planning to take their epilepsy drug into clinical trials because that would put some of their eggs into a second basket. If they do that, I'll buy more.
There are certainly questions about the competence of AVXL's management in the past. The new president seems to be righting the ship. People seem to be claiming to be disappointed by the data on the drug, but given that no other drug has displayed any sort of long-term efficacy against Alzheimer's, the fact that AVXL's drug seems to have SOME efficacy for about 6 months or so is something very positive. These are early days in the clinical trials. It could be that the dosing schedule or the dosage is not correct. Sometimes these drugs are more effective when taken spaced out further -- who knows? We sure don't. But ANY kind of positive result with Alzheimer's is a plus, not a minus.
I consider this to be a far more risky investment than CTIX and I have only a relatively small investment now in AVXL. I hope that they are planning to take their epilepsy drug into clinical trials because that would put some of their eggs into a second basket. If they do that, I'll buy more.
(1)
(0)